CL2011000805A1 - Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. - Google Patents
Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.Info
- Publication number
- CL2011000805A1 CL2011000805A1 CL2011000805A CL2011000805A CL2011000805A1 CL 2011000805 A1 CL2011000805 A1 CL 2011000805A1 CL 2011000805 A CL2011000805 A CL 2011000805A CL 2011000805 A CL2011000805 A CL 2011000805A CL 2011000805 A1 CL2011000805 A1 CL 2011000805A1
- Authority
- CL
- Chile
- Prior art keywords
- stroke
- atrial fibrillation
- prevention
- prepare
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende etexilato de dabigatran; y su uso para prevenir o tratar trombosis y reducir el riesgo de un accidente hemorrágico mayor, ictus hemorrágico, ictus intracraneal y fibrilación auricular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11341308P | 2008-11-11 | 2008-11-11 | |
US23756609P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000805A1 true CL2011000805A1 (es) | 2011-10-28 |
Family
ID=41463077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000805A CL2011000805A1 (es) | 2008-11-11 | 2011-04-12 | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20110251160A1 (es) |
EP (1) | EP2358367A1 (es) |
JP (1) | JP2013510074A (es) |
KR (1) | KR20110082563A (es) |
CN (2) | CN103340860A (es) |
AR (1) | AR074108A1 (es) |
AU (1) | AU2009315731A1 (es) |
BR (1) | BRPI0921353A2 (es) |
CA (1) | CA2738885A1 (es) |
CL (1) | CL2011000805A1 (es) |
IL (1) | IL211854A0 (es) |
MX (1) | MX2011004534A (es) |
NZ (1) | NZ592613A (es) |
RU (1) | RU2530645C2 (es) |
TW (1) | TW201022238A (es) |
WO (1) | WO2010055023A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0921479A2 (pt) | 2008-11-11 | 2016-01-12 | Boehringer Ingelheim Int | método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorado perfil de segurança em relação à terapia convencional com varfarina |
WO2011156587A2 (en) * | 2010-06-09 | 2011-12-15 | Daiichi Sankyo, Inc. | Methods and systems for anticoagulation risk-benefit evaluations |
EP2550966B1 (de) * | 2011-07-25 | 2016-10-19 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
CN103127109B (zh) * | 2013-02-05 | 2014-08-13 | 南京华威医药科技开发有限公司 | 含达比加群酯或其盐和水合物的药用组合 |
RU2595238C1 (ru) * | 2015-05-18 | 2016-08-20 | Галина Александровна Суханова | Способ лечения подострых венозных тромбозов различной локализации |
RU2762945C1 (ru) * | 2021-03-02 | 2021-12-24 | Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) | Способ антикоагулянтной терапии и профилактики тромботических осложнений у пациентов с тяжелым повреждением головного мозга в хроническом критическом состоянии |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524203A (ja) * | 2003-04-24 | 2006-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | トロンビンの過剰形成及び/又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
CA2657266A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
-
2009
- 2009-11-10 EP EP09748791A patent/EP2358367A1/en not_active Withdrawn
- 2009-11-10 AR ARP090104348A patent/AR074108A1/es unknown
- 2009-11-10 BR BRPI0921353A patent/BRPI0921353A2/pt not_active IP Right Cessation
- 2009-11-10 MX MX2011004534A patent/MX2011004534A/es not_active Application Discontinuation
- 2009-11-10 CA CA2738885A patent/CA2738885A1/en not_active Abandoned
- 2009-11-10 CN CN2013101422468A patent/CN103340860A/zh active Pending
- 2009-11-10 US US13/128,463 patent/US20110251160A1/en not_active Abandoned
- 2009-11-10 JP JP2011535126A patent/JP2013510074A/ja active Pending
- 2009-11-10 WO PCT/EP2009/064875 patent/WO2010055023A1/en active Application Filing
- 2009-11-10 AU AU2009315731A patent/AU2009315731A1/en not_active Abandoned
- 2009-11-10 NZ NZ592613A patent/NZ592613A/xx not_active IP Right Cessation
- 2009-11-10 RU RU2011123367/15A patent/RU2530645C2/ru not_active IP Right Cessation
- 2009-11-10 CN CN2009801448120A patent/CN102209545A/zh active Pending
- 2009-11-10 TW TW098138139A patent/TW201022238A/zh unknown
- 2009-11-10 KR KR1020117010629A patent/KR20110082563A/ko not_active Application Discontinuation
-
2011
- 2011-03-22 IL IL211854A patent/IL211854A0/en unknown
- 2011-04-12 CL CL2011000805A patent/CL2011000805A1/es unknown
-
2013
- 2013-09-06 US US14/019,906 patent/US20140045898A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103340860A (zh) | 2013-10-09 |
US20110251160A1 (en) | 2011-10-13 |
CA2738885A1 (en) | 2010-05-20 |
BRPI0921353A2 (pt) | 2015-12-29 |
NZ592613A (en) | 2013-06-28 |
WO2010055023A1 (en) | 2010-05-20 |
IL211854A0 (en) | 2011-06-30 |
JP2013510074A (ja) | 2013-03-21 |
RU2530645C2 (ru) | 2014-10-10 |
CN102209545A (zh) | 2011-10-05 |
RU2011123367A (ru) | 2012-12-20 |
KR20110082563A (ko) | 2011-07-19 |
AU2009315731A1 (en) | 2010-05-20 |
TW201022238A (en) | 2010-06-16 |
MX2011004534A (es) | 2011-05-24 |
EP2358367A1 (en) | 2011-08-24 |
AR074108A1 (es) | 2010-12-22 |
US20140045898A1 (en) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
BRPI0908168A2 (pt) | composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes | |
CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
CO6430497A2 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
CL2011001817A1 (es) | Forma de dosificacion unitaria solida oral en forma de tableta que comprende un nucleo y un recubrimiento externo, en donde el nucleo comprende alisquireno o a una sal del mismo, y el recubrimiento en un recubrimiento de pelicula, util para el tratamiento de una enfermedad o condicion en una poblacion pediatrica. | |
BR112015026631A2 (pt) | compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero | |
CO6311083A2 (es) | 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva | |
MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
ECSP10010567A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
CL2008003558A1 (es) | Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga. | |
AR088497A1 (es) | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina | |
TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure |